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Abstract
Background: The primary unit of tuberculosis (TB) medical care in China is the county TB dispensary or county
designated hospital (CTD), where patients can receive free diagnosis and treatment. However, a substantial number
of patients seek their anti-TB treatment from general health facilities (Non-CTDs). This study aimed to investigate
the first anti-TB treatment experience and choice of health facilities of retreated TB patients and their determinants.
Methods: A cross-sectional study was conducted in Jiangsu, Shandong and Sichuan provinces. All registered re-treated
TB patients were investigated using a structured questionnaire covering information on demographics, socio-economic
characteristics, and previous anti-TB treatment experiences.
Results: Totally, 75.3% of 544 patients visited CTD directly for initial treatment. Patients who were female (OR:1.71, 95% CI:
1.01-2.87), over 40 years of age (OR:2.80, 95% CI: 1.24-6.33), from Jiangsu (OR:3.07, 95% CI: 1.57-6.01) and Sichuan (OR:4.47,
95% CI: 2.29-8.73) and those diagnosed before 2005 (OR:6.87, 95% CI: 4.24-11.13) had a significant higher risk receiving
their initial treatment at a non-CTD. Patients were more likely to have standardized diagnosis and treatment regimens in
CTD (89.8%) than in non-CTDs (65.9%). Patients treated in non-CTDs versus in CTD had a lower possibility to complete
their treatment course during first TB episode (χ2 = 3.926, P = 0.048), but there was no significant difference in the cure
rate between different facilities (CTD 60.8%, Non-CTDs 59.1%). Patients in non-CTDs incurred higher costs (1,360 CNY)
than those treated in CTD (920CNY).
Conclusion: CTD play a key role in the National Tuberculosis Control Program. Patients should be guided to seek health
care in county designated hospital, where they are more likely to receive appropriate examinations, treatment regimens
and rigorous supervision, and to bear a lighter economic burden.
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Background
Tuberculosis (TB) remains a major global health prob-
lem, responsible for ill health among millions of people
each year [1]. TB is one of the world’s deadliest commu-
nicable diseases. There were 9.0 million new TB cases in
2014 and 1.5 million TB deaths, including 320,000
deaths among HIV-positive people [1]. With the third
heaviest burden of TB worldwide over the past two de-
cades, China holds 12% of global TB patients [1]. China’s
National TB control Program started to implement the
international recommended directly observed treatment,
short-course (DOTS) strategy in 1991, and expanded the
DOTS programme to the entire country by 2005 [2].
Over the past 20 years, the prevalence and mortality
rates of TB has been reduced by half. The estimated
smear-positive prevalence decreased from 170/100,000
in 1990 to 59/100,000 in 2010 and the mortality rate
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declined rapidly at an average rate of 8.6% per year dur-
ing the period between 1990 and 2010 [3, 4].
Nevertheless, China still faces daunting challenges and
difficulties in TB control, and a rapid multi-drug-resistant
(MDR) TB increase is one of them. There are approxi-
mately 120,000 new MDR-TB cases annually in China, ac-
counting for 24% of the global MDR-TB burden [5].
Several studies have shown that pervious treatment is the
strongest determinant of MDR-TB [6–8]. The acquired
drug-resistant TB mainly result from incompliance to
treatment, uncompleted treatment, irregular treatment
and unqualified health services. A study in Moldova found
that 7.2-9.2% patient turned from non-MDR-TB to MDR-
TB during their treatment course, likely due to unregu-
lated treatment and nosocomial transmission [9].
The administration structure in rural China is three tiers
from village to town to county. There were about 2800
counties in total according toNew Statistical Year books
published by National Bureau of Statistics of China in
2016 [10]. In general, each county has about 10–15 town-
ships and each township administers 10–20 villages. The
health service in rural is also a three-tier system, with 1–2
county-level hospitals, one township hospital or health
center in township level and village health station in each
village. The basic unit of TB health care in China is the
specialized County TB dispensary or County designated
TB clinics (CTD), which has been set in more than 2500
Chinese counties. The CTDs take the responsibilities of
TB diagnosis, treatment and patient management guided
by the National TB control program. TB diagnosis is
microscopy-based following the guideline of the WHO
and IUTLD. The recommended treatment regimen for
new TB case and retreated TB cases were 2HRZS/4HR
and 2HRZSE/6HRE [11].
However, it is common in rural areas that patients initi-
ated their health care seeking for cough and other TB
symptoms in general health facilities instead of CTD, such
as village health stations, township and county hospitals.
Most of these health facilities (non-CTDs) don’t have the
capacity for TB treatment. The non-CTD’s role in China’s
TB control program is to refer suspected TB patients to
CTDs for standardized diagnosis, treatment and manage-
ment. It is unclear whether TB patients are treated and
managed equally well in the two types of facilities. Our
study investigated the first anti-TB treatment experience
and choice of health facilities of retreated TB patients and
their determinants in three provinces.
Study population and methods
Study Setting
Three provinces were purposively selected for the con-
sideration of geographic and economic variation in 2012
and 2013. Shandong and Jiangsu are plain provinces in
eastern China while Sichuan is a province in western
China with vast mountainous areas. In 2013, the popula-
tions of Jiangsu, Shandong, and Sichuan Provinces were
79.39, 97.33, and 81.07 million respectively. The average
annual income for rural residents was 1,739 US Dollars
(USD) per capita in Jiangsu, 1,343 USD in Shandong and
987 USD in Sichuan, while the national average was
1,123 USD in 2011 [12]. Eleven counties, 4 from Jiangsu
province, 3 from Shandong, and 4 from Sichuan prov-
ince were selected covering a population of 5, 4 and 4
million respectively in the three provinces.
Data collection
All registered 544 active pulmonary TB patients with a
history of at least one anti-TB treatment were investigated
after written informed consent was obtained. Among
them, 200 were from Jiangsu, 149 from Shandong and 195
from Sichuan.
Physicians, who had undergone a 1-day training course
for the study, interviewed the subjects at the time of TB
diagnosis.
A structured questionnaire was applied covering informa-
tionon general demographic and social-economic charac-
teristics, disease history, previous anti-TB treatment
experiences, TB related health expenditures and disease
profile. Expenditures on TB related health care during the
whole treatment course were self-reported by patients. Dir-
ect medical costs included expenditures onexamination-
sand testing, medication and hospitalization, indirect costs
were expenditures on transportation, accommodation, food
and other related costs for each visit.
Data analysis
Data were double entered with EpiData 3.1 (Denmark)
and analyzed using SPSS for Windows version 16.0 (SPSS,
Chicago, IL, USA). Descriptive statistics were applied in-
cluding medians, means, proportions and frequencies. Ei-
ther Chi-square test or Mann–Whitney U test were used
in univariate analyses to identify factors associated with
the outcomes of interest. A logistic regression model was
used to examine the associations of interest and adjust
odds ratios (aOR) and 95% confidence intervals (95% CIs)
were calculated.
Results
General characteristics of subjects
A total of 544 previously treated TB patients were en-
rolled in the study, including 402 (74.2%) male and 140
(25.8%) female patients, 17 to 98 years of age (mean:
55.29, standard deviation: 15.33 years). Of them, 383
(70.5%) were farmers and 339 (62.7%) had no more than
6 years of education; 531 (98.2%) had medical insurance,
mainly covered by New Rural Cooperative Medical
Insurance (90.2%).
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Diagnosis and treatment experience
A majority of the TB patient had one previous anti-TB
treatment episode, 10.3% had twice and 2.2% had three
times before investigation. Among the patients, 380
(70.1%) received their first TB diagnosis after 2005 when
the DOTS strategy had been adopted widely in the coun-
try. Three quarters (75.3%, 409/544) of the patients were
treated in the CTD for their first treatment episode, and
others were treated in either township hospitals (5.9%, 32/
544) or county hospitals (16.5%, 90/544). For the patients
who had more than one treatment episode, nearly all the
patients who were treated in township (100%, 32/32) or
county hospitals (98.5%, 88/90) first time had a referral to
CTD and totally 98.5% (536/544) of the patients chosen
CTD for their second episode (Fig. 1).
Logistic regression analysis was applied to determine
the associations of the selection of treatment facilities with
patients’ demographics, socio-economic status, and times
of treatment episodes. It was found that gender, age, re-
gion, first diagnosis year and average annual income were
significantly associated with the selection of treatment fa-
cilities. Compared to other patients, increased odds for
visiting a non-CTD for their first course of anti-TB treat-
ment were observed in females (OR: 1.71, 95% CI:1.01-
2.87), those more than 40 years of age (OR: 2.80, 95%
CI:1.24-6.33), those from Jiangsu (vs. Shandong, OR: 3.07,
95% CI:1.57-6.01) and Sichuan (vs. Shandong, OR: 4.47,
95% CI: 2.29-8.73), and those diagnosed before 2005 (OR:
6.87, 95% CI: 4.24-11.13).No statistically significant associ-
ations were found with the times of treatment episodes,
marital status, education level, occupation and medical in-
surance status of patients (Table 1).
Laboratory examinations and chemotherapy regimens
during first anti-TB treatment episode
Chest X ray examination (92.65%) and sputum smear test
(81.80%) were mostly commonly used for TB diagnosis.
Among the 113 patients treated in non-CTDs, 48.89%
received sputum smear tests, and the proportion was
significantly lower than the patients treated in CTD (379
and 92.67%, P < 0.001). A trend was also observed for the
proportion of patients receiving sputum culture or drug
sensitive test (P < 0.001). On the contrary, patients treated
in non-CTDs had a higher possibility to receive chest fluor-
oscopy (P < 0.001), blood routine tests (P = 0.033) and
Computerized Tomography (CT) test (P < 0.001) (Table 2).
Totally, 87 patients (65.9%), who were treated in non-
CTDs during their first anti-TB treatment episode,
received standardized regimen. The proportion was sig-
nificantly lower than those treated in CTD (89.8%, P <
0.001) (Table 3). About 16.1% were treated using loose
drugs or other combinations. It was found that some pa-
tients may only take isoniazid and rifampicin while
treated in non-CTDs, or may had a treatment course
shorter or longer than the standardized duration, or re-
ceived 2nd line anti-TB drug without drug susceptibility
testing. It was found that 36 of the 423 patients (8.5%)
had received 2nd-line anti-TB drugs during their initial
treatment. The most common drug was fluoroquino-
lone, which was used by 33 patients.
Treatment adherence of patients during first anti-TB
treatment episode
Most patients (83.4%, 423/507) completed their first
treatment course and 60.4% (304/503) were cured after
the treatment (Table 3). The accomplishment propor-
tions of patients treated in CTD and Non-CTDs were
85.2% and 77.4%, respectively; Patients treated in non-
CTDs had a lower possibility to complete their treat-
ment course during first TB episode (P = 0.048), but the
cure rates showed no significant difference between
CTD (60.8%) and non-CTDs (59.1%). Among the 84 pa-
tients who had an interruption for their treatment
course, 55.6% perceived themselves to be healthy and
felt no need to complete the course; 21.0% gave up due
to serious side effects of anti-TB drugs. Other reasons
for treatment interruption included heavy economic bur-
den (16.0%) and moving to other regions (3.7%).
Fig. 1 Pathways of health facilities during previous anti-TB episodes
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Economic burden for patients during first anti-TB treat-
ment episode
Our study showed that the average financial burden on
patients was 2382 CNY (median 1,012 CNY, [IQR 500–
2968 CNY]). Half of the patients incurred costs of more
than 17% of their individual annual income and over 7%
of their annual family income. The median financial bur-
den on patients treated in CTD and non-CTDs was 920
CNY [450–2,800 CNY] and 1,360 CNY [720–3,000
CNY], respectively (Table 4).
Discussion
The basic principles of care for TB patients are the same
worldwide: a diagnosis should be established promptly
and accurately; standardized treatment regimens of
proven efficacy should be used with appropriate treat-
ment support and supervision; and the response to treat-
ment should be monitored [13].
In China, the primary TB medical care unit is the
CTD, where patients receive free diagnosis and treat-
ment. But our study showed that there were still some
Table 1 Logistic regression analyses for determinants affecting patients’ choices of health facilities (Non-CTD vs. CTD)
Categories CTDs Non-CTDs cOR (95% CI) aOR (95% CI)
No (%) No (%)
Gender (female/male)
Male 308 (76.62) 94 (23.38) 1.357 (0.882-2.088) 1.705 (1.014-2.866)
Female 99 (70.71) 41 (29.29)
Marriage (unmarried/married)
Married 363 (74.08) 127 (25.92) 2.566 (1.068-6.164) 1.342 (0.477-3.774)
Unmarried 44 (88.00) 6 (12.00)
No. of previous TB episodes
1 354 (74.37) 122 (25.63)
2 (2 vs.1) 47 (83.93) 9 (16.07) 0.556 (0.265-1.167) 0.451 (0.197-1.034)
3-4 (3–4 vs.1) 8 (66.67) 4 (33.33) 1.451 (0.429-4.903) 1.868 (0.460-7.574)
First diagnosis year* (before/after)
Before 2005 83 (51.23) 79 (48.77) 5.507 (3.623-8.371) 6.869 (4.241-11.127)
After 2005 324 (85.26) 56 (14.74)
Education degree (≥6/<6)
< 6 years 251 (74.04) 88 (25.96) 0.865 (0.576-1.299) 0.825 (0.490-1.392)
≥ 6 years 155 (76.73) 47 (23.27)
Insurance (insured/non)
Non-insured 7 (70.00) 3 (30.00) 0.766 (0.195-3.005) 0.682 (0.148-3.143)
Insured 402 (75.28) 132 (24.72)
Income quartile#
Group 1 111 (77.62) 32 (22.38) 1.077 (0.626-1,852) 0.922 (0.491-1.730)
Group 2 (2 vs.1) 116 (76.32) 36 (23.68)
Group 3 (3 vs.1) 94 (73.44) 34 (26.56) 1.255 (0.720-2.186) 1.105 (0.569-2.147)
Group 4 (4 vs.1) 73 (69.52) 32 (30.48) 1.521 (0.858-2.694) 1.893 (0.923-3.882)
Occupation (farmer/non)
Non-farmer 119 (74.38) 41 (25.63) 0.944 (0.618-1.443) 1.222 (0.698-2.138)
Farmer 289 (75.46) 94 (24.54)
Age (≥40/<40)
< 40 years old 73 (86.90) 11 (13.10) 2.509 (1.288-4.887) 2.800 (1.239-6.328)
≥ 40 years old 328 (72.57) 124 (27.43)
Provinces
Shandong 130 (87.25) 19 (12.75)
Jiangsu (JS vs.SD) 151 (75.50) 49 (24.50) 2.220 (1.244-3.963) 3.070 (1.568-6.010)
Sichuan (SC vs. SD) 128 (65.64) 67 (34.36) 3.581 (2.036-6.300) 4.467 (2.285-8.734)
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patients who visited non-CTDs for their anti-TB treat-
ment. In our study, only 75.3% of the subjects chose
CTDs for anti-TB treatment during their first episode,
and the rest of patients received anti-TB services from
non-designated health care facilities. Patients who were
female, elderly, had higher income and were diagnosed
before 2005 were more likely to visit non-CTDs [14].
Previous studies also demonstrated that female and eld-
erly patients tended to visit hospitals nearby or delay
seeking for help, and individuals with higher income
preferred high-ranking comprehensive hospitals [15–17].
The phenomenon that patients didn’t seek service from
CTD before 2005 may have resulted from the low
popularization rate of DOTS strategy.
For the quality of TB care, one surprising finding was
that the patients treated in non-CTDs had a lower possi-
bility to receive proper laboratory examinations for diag-
nosis. Sputum smear microscopy, the primary method
for detecting TB, is required for each suspect. However,
only 48.89% of the patients treated in non-CTDs re-
ceived such examination. Lack of bacteriological con-
firmation in non-CTDs was also reflected by a low
proportion of patients who received sputum culture tests
or drug sensitive tests. Because the bacteriological con-
firmation of TB is essential for TB diagnosis, patients
treated in non-CTDs would have a worse scenario than
those treated in CTDs [18].
Our study also revealed that non-CTDs were less likely
to provide standardized therapeutic strategy and treatment
supervision compared with CTD. The TB component of
the infectious and endemic disease control (IEDC-TB) pro-
ject in the People’ Republic of China indicated that new
smear-positive cases should be treated with 2HRZS/4HR
regimen [11, 19]. Patients treated in non-CTDs had a lower
possibility to obtain the standardized chemotherapy regi-
mens than those treated in CTD and a previous study by
Chinese National Center for TB Control and Prevention
showed similar results that only a small proportion of TB
cases in hospitals (non- CTDs) were treated with appropri-
ate NTP/WHO treatment regimens [20]. As improper
therapeutic strategy could result in an extra burden not
only to the patients but also to the community by increas-
ing chances of drug resistance development, non-CTDs
were proved to be less efficient in TB control in this re-
spect. Meanwhile, only 77.4% cases treated in general hos-
pitals completed their first treatment course; more than
half of the patients who quitted the course felt good about
themselves and stopped the treatment without doctors’ per-
mission, indicating that lacking of supervision could led to
a lower rate of treatment completion in general medical
institutions.
The medium financial burden and medical cost in non-
CTDs tended to be higher compared with those in CTD,
although the differences were not statistically significant.
Table 3 Treatment regimen and outcome of initial treatment
Characteristics Non-CTD CTD Total P-
value*No. (%) No. (%) No. (%)
Regimen 2HRZS/4HR+ 87 (65.9) 362 (89.8) 449 (83.9) <0.001
Others 45 (34.1) 41 (10.2) 86 (16.1)
Outcome Cure 68 (59.1) 240 (61.2) 308 (60.7) <0.001
Treatment completed 0 (0.0) 37 (9.4) 37 (7.3)
Treatment failed 21 (18.3) 57 (14.5) 78 (15.4)
Treatment interrupted 26 (22.6) 58 (14.8) 84 (16.6)
Medium length of treatment (p25, p75) (M) 6 (5,7) 6 (6,6) 6 (5,7) 0.279**
+ Recommended treatment regimen for new TB case
* Chi-square test
** Mann–Whitney U test
Table 2 Laboratory examinations during first anti-TB episode
Examinations Total number CTD Non-CTD P
N % N %
Sputum smear test 445 379 92.67 66 48.89 <0.001
Sputum culture/Drug sensitive test 73 67 16.38 6 4.44 <0.001
Chest fluoroscopy 123 67 16.38 56 41.48 <0.001
Chest X ray examination 504 379 92.67 125 92.59 0.978
Blood routine test 255 181 44.25 74 54.81 0.033
CT 107 59 14.43 48 35.56 <0.001
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The exemption policy of TB treatment is only provided to
the patients who have smear positive results from CTD. In
addition, there is an increased hospital dependence on fee-
for-service revenue, which promotes doctors in non-CTDs
to provide additional clinical services and prescribe more
drugs in order to maximize their profits [21]. TB has been
regarded as a poverty-related disease, as it disproportion-
ately affects the most economically disadvantaged strata of
society [22]. Previous studies have documented that high fi-
nancial burden is an important influencing factor for pa-
tient health care seeking behavior [23, 24] and may deter
patients from seeking treatment [25].
This study had several limitations. First, only 11 coun-
ties from three provinceswere selected in the study, and
therefore, a caution should be taken when extrapolating
the results of this study. Second, we only studied the pa-
tients who were registered in CTD, and patients who did
not register might behave differently in seeking health
care. Third, information on income, expenditure, and
time was based on self-reporting, and there might be re-
call bias, although trained interviewers tried to obtain
information from different sources to reduce the bias.
Conclusions
In conclusion, during the past twenty years, CTD played an
important role in the national TB control programme, and
provided better TB care services as compared to non-
CTDs. With the progress of China’s TB control program
and improvement of health service, TB patients should be
guided to the county designated hospitals or clinics, where
they are more likely to receive specialized examinations, ap-
propriate treatment and rigorous supervision, and to bear a
lighter economic burden. Findings from this study suggest
that potential TB patients in rural area should be targeted
for tailored health education on TB related health policy,
especially the important role of TB designated hospital.
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Table 4 Economic burden for patients during first anti-TB episode
Cost (CNY) Response No. CTD (Median, IQR) Non-CTD (Median, IQR) P*
Total 358 1055 [505,3700] 2030 [1028,3016] 0.001
Medical costs 504 1000 [400,3000] 2000 [600,3000] 0.001
Non-medical costs 359 63 [20,420] 30 [1,100] 0.011
Transportation 498 16 [10,30] 16 [1,30] 0.803
Accommodation and food 424 10 [0,20] 0 [0,20] 0.032
Other costs 364 10 [0,200] 0 [0,20] <0.001
Covered by insurance 393 0 [0,800] 0 [0,800] 0.149
Patient financial burden 352 920 [450,2800] 1360 [720,3000] 0.003
*Mann–Whitney U test
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